Incyte taps David Gryska to be its new CFO

Chutes and Ladders

Welcome to this week's Chutes and Ladders, our roundup of hirings and retirings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter) or Emily Mullin (email | Twitter) and we will feature it here at the end of each week.

Incyte taps David Gryska to be its new CFO

David Gryska, a former finance executive at Celgene ($CELG) and Scios, joined Incyte ($INCY) as the company's new chief financial officer and executive vice president. He succeeds David Hastings, who has held the position since 2003 and will help with the transition, according to the company. Incyte has a shot at blockbuster sales alongside partner Novartis ($NVS) with its drug ruxolitinib for myelofibrosis, which met its primary endpoint in a 222-patient trial on polycythemia vera earlier this year. More

Incyte
David Gryska is the new executive VP and CFO.

Biotech

Navidea Biopharmaceuticals ($NAVB) has appointed Rick Gonzalez as CEO. Release

Bart Filius, vice president and CFO of Sanofi ($SNY) Europe, will join Galapagos as chief financial officer. Release

Cydan Development has appointed Vered Bisker-Leib as chief business officer. Release

Apexigen has appointed Dr. Ovid Trifan as vice president of clinical development and Amy Wong as vice president of finance. Release

Donald Morel announced he would step down as chairman of West Pharmaceutical Services' ($WST) board of directors in May, 2015. Release

> CytRx ($CYTR) has appointed Steven Kriegsman as chairman of the board. Release

> GenSpera ($GNSZ) has appointed Dr. Melanie Thomas as medical advisor. Release

> Bacterin has added three senior executives to its hybrid sales channel. Jeff Whitaker has joined the company as regional vice president in the Southeast; Doug Helling has joined as regional vice president in the South; and Ed Daily has joined the company as regional vice president in the Northeast. Release

DaVita Labs hired Dr. Lorne Holland to be its chief lab officer. Release

Pharma

PuriCore CEO Michael Ashton is retiring. Release

Pharmalink elected Bengt Julander as its new chairman. Release

Richard Aleman will lead regulatory compliance at Pharmatech, and Warren Baker joined as CEO. Release | Release

Medical Devices

Lisa Garrett has joined ForSight VISION5 as vice president of finance and administration. Release

Mazor Robotics promoted Christopher Prentice to be CEO of its U.S. subsidiary. Release

Drug Delivery

Catalent appointed Steven Fasman to be its senior vice president and general counsel. Release

 

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.